

SyrSpend® SF Compatibility Table

Updated October 2025

Active Ingredient/Strength	API Source	BUD Refrigerated (days)	BUD Room Temperature (days)	Container Closure
^{4,11} Acetaminophen 50mg/mL	Bulk Powder	90 	90 	Amber Glass
^{4,15} Allopurinol 20mg/mL	Bulk Powder	90 	90 	Amber Glass
^{3,4} Amitriptyline HCl 10mg/mL	Bulk Powder	90 	90 	Amber Glass
^{2,6} Amlodipine Besylate 1mg/mL	Bulk Powder	90 	90 	Amber Glass
¹ Azithromycin 40mg/mL*	Bulk Powder	60 	7 	Amber PET
¹ Bismuth Subsalicylate 17.5mg/mL	Bulk Powder	14 	14 	Amber PET
¹ Budesonide 0.25mg/mL	Bulk Powder	90 	90 	Amber PET
¹ Buspirone 2.5mg/mL	Bulk Powder	90 	90 	Amber PET
¹ Cephalexin 50mg/mL*	Bulk Powder	30 	14 	Amber PET
¹ Chlorpromazine HCl 100mg/mL	Bulk Powder	90 	90 	Amber PET
¹ Citalopram HBr 2mg/mL	Bulk Powder	90 	90 	Amber PET
^{3,5} Clonazepam 0.2mg/mL	Bulk Powder	90 	90 	Amber Glass
^{12,15} Clopidogrel 5mg/mL	Tablets	30 	n/a	Amber Glass
¹ Cyanocobalamin 0.2mg/mL	Bulk Powder	90 	90 	Amber PET
^{6,11} Dapsone 2mg/ml	Bulk Powder	90 	90 	Amber Glass
^{5,15} Dexamethasone 1mg/mL	Bulk Powder	90 	90 	Amber Glass
^{2,5} Enalapril maleate 1mg/mL	Bulk Powder	90 	90 	Amber Glass
¹ Famotidine 8mg/mL	Bulk Powder	90 	90 	Amber PET
^{8,15} Folic Acid 1mg/mL	Bulk Powder	90 	90 	Amber Glass
^{11,12} Griseofulvin 25mg/mL	Bulk Powder	90 	90 	Amber Glass
^{3,7} Haloperidol 0.5mg/mL	Bulk Powder	90 	90 	Amber Glass
^{2,8} Hydrochlorothiazide 2mg/mL	Bulk Powder	90 	90 	Amber Glass
^{2,8} Hydrochlorothiazide 5mg/mL	Bulk Powder	90 	90 	Amber Glass
^{11,14} Indomethacin 5mg/mL	Bulk Powder	90 	90 	Amber Glass
^{9,11} Levofloxacin 50mg/mL	Bulk Powder	90 	90 	Amber Glass
^{2,4} Lisinopril 1mg/mL	Bulk Powder	90 	90 	Amber Glass
^{3,7} Lorazepam 1mg/mL	Bulk Powder	90 	90 	Amber Glass
¹ Meloxicam 0.2mg/mL	Bulk Powder	90 	90 	Amber PET
^{2,9} Metoprolol Tartrate 10mg/mL	Bulk Powder	90 	90 	Amber Glass

^{3,8} Naltrexone HCl 1mg/mL	Bulk Powder	90 	90 	Amber Glass
^{4,11} Naproxen 25mg/mL	Bulk Powder	90 	90 	Amber Glass
^{9,15} Ondansetron HCl 0.8mg/mL	Bulk Powder	90 	90 	Amber Glass
¹ Orphenadrine Citrate 5mg/mL	Bulk Powder	90 	90 	Amber PET
^{2,8} Pentoxifylline 20mg/mL	Bulk Powder	90 	90 	Amber Glass
^{3,9} Pregabalin 20mg/mL	Bulk Powder	90 	90 	Amber Glass
^{10,15} Propranolol HCl 0.5mg/mL	Bulk Powder	90 	n/a	Amber Glass
^{16,15} Propranolol HCl 5mg/mL	Bulk Powder	90 	n/a	Amber Glass
^{3,4} Sertraline HCl 10mg/mL	Bulk Powder	90 	90 	Amber Glass
^{2,10} Spironolactone 2mg/mL	Bulk Powder	90 	n/a	Amber Glass
^{2,10} Spironolactone 2.5mg/mL	Bulk Powder	90 	n/a	Amber Glass
^{10,15} Tacrolimus 0.5mg/mL	Bulk Powder	90 	n/a	Amber Glass
^{7,15} Tacrolimus 1mg/mL	Bulk Powder	90 	90 	Amber Glass
^{11,13} Terbinafine HCl 25mg/mL	Bulk Powder	90 	90 	Amber Glass

*additional ingredients added, please review full formulation

n/a = not applicable/not tested

References:

1. Kegele C, Dijkers E, Polonini H. Physiochemical and microbiological stability of commonly prescribed APIs in Syrspend SF PH4: a comprehensive compatibility study. IJPC. 2025; 29(3): 144-160.
2. Kegele C, Dijkers E, Polonini H. Antimicrobial stability, pH, and physical appearance of cardiovascular drug suspensions in Syrspend SF PH4: a complementary evaluation. IJPC.2025; 29(4): 219-227
3. Kegele C, Dijkers E, Polonini H. Antimicrobial effectiveness and physiochemical stability of compounded psychiatric and neurological drug suspensions in Syrspend SF PH 4. IJPC. 2025; 29(4): 228-236.
4. Polonini HC, Loures S, de Araujo ED, Brandão MAF and Ferreira AO. Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in Syrspend SF PH4 Oral Suspensions. Int J Pharm Compd. 2016;20:426-434.
5. Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MAF. Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D and Thiamine in Syrspend SF PH4 Oral Suspensions. Int J Pharm Compd. 2016;20:167-174.
6. Ferreira AO, Polonini HC, Silva SL, Patrício FB, Brandão MA, Raposo NR. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in Syrspend® SF PH4 oral suspensions. J Pharm Biomed Anal 2016;118:105-112.
7. Polonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride,

tacrolimus monohydrate, terbinafine, tramadol hydrochloride, valsartan in SyrSpend® SF PH4 oral suspensions. *Pharmazie*. 2016;71:185-91.

8. Polonini HC, Silva SL, de Almeida TR, Brandão MAF and Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. *Eur J Hosp Pharm*. 2016 (Published Online First).
9. Ferreira AO, Polonini HC, Loures da Silva S, Cerqueira de Melo VA, de Andrade L and Brandão MAF. Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabalin, and Riboflavin in SyrSpend SF pH4 Oral Suspensions. *Int J Pharm Compd*. 2017;21:255-263.
10. Polonini H, da Silva SL, Brandão MAF, Bauters T, De Moerloose B, Ferreira AO. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4. *Int J Pharm Compd*. 2018 Nov-Dec;22(6):516-526.
11. Kegele C, Dijkers E, Polonini H. SyrSpend SF PH4 as a safe vehicle for extemporaneous oral suspensions: microbiological stability of seven APIs. *Int J Pharm Compd*. 2025; 29(5): 420-429.
12. Polonini H, da Silva SL, de Araújo EP, Ferreira AO, Anagnostou K, Dijkers ECF. Stability of Azathioprine, Clonidine hydrochloride, Clopidogrel bisulfate, Ethambutol hydrochloride, Griseofulvin, Hydralazine hydrochloride, Nitrofurantoin and Thioguanine oral suspensions compounded with SyrSpend® SF PH4. *Int J Pharm Compd*. 2020 May-June;24(3):252-262.
13. Polonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride, valsartan in SyrSpend® SF PH4 oral suspensions. *Pharmazie*. 2016;71:185-91.
14. Mansourian, M.; Dijkers, E.; Silva, C.C.V.; Polonini, H.C. Compatibility of Commonly Used Active Pharmaceutical Ingredients in a Ready-to-Use Oral Suspending Vehicle. *Pharmaceutics* 2023; 15: 2388.
15. Kegele C, Dijkers E, Polonini H. Microbiological and physical stability of extemporaneous oral suspensions compounded with SyrSpend SF PH4. *Int. Journ Pharm Compd*. 2025; 29(5): 409-419.
16. Dijkers ECF, Nanhekhan V, Thorissen A. Updated Stability Data of Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil. *Int J Pharm Compd*. 2017;21:240-241.